Clinical Trial Update: Efficacy and Pharmacodynamic Study of Panzem® NCD in Patients With Hormone-Refractory Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study assessing the efficacy and pharmacodynamics of Panzem NCD in patients with hormone-refractory prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Panzem NCD

Snippet

Sponsor: CASI Pharmaceuticals, Inc. | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED